Posted in Constellation in the News, Newsroom
CAMBRIDGE, Mass. – January 17, 2012 – Constellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop innovative treatments for [...]
Read more »
Posted in Constellation in the News, Newsroom
Targeting Chromatin Adaptors to Suppress MYC, a Gene Dysregulated in Wide Range of Malignancies, Represents Promising Therapeutic Approach in Oncology CAMBRIDGE, Mass. – September 26, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced the publication of a paper in the Proceedings of the National Academy of [...]
Read more »
Posted in Constellation in the News, Newsroom
CAMBRIDGE, Mass. – June 6, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life [...]
Read more »
Posted in Constellation in the News
- Dr. Michael Cooper Appointed Chief Medical Officer - Dr. Steven Paul Elected to Board of Directors CAMBRIDGE, Mass. – February 1, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the expansion of its leadership team with the [...]
Read more »
Posted in Constellation in the News, Newsroom
MMRF Biotech Investment Awards Provide Funding to Industry to Advance Myeloma Therapies NORWALK, Conn. – January 6, 2011 – The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, [...]
Read more »
Posted in Constellation in the News, Newsroom
-Accomplished Executive Brings Broad Drug Discovery and Development Experience- CAMBRIDGE, MA – January 4, 2011 – Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a [...]
Read more »
Posted in Constellation in the News, Newsroom
-Proceeds to Broaden Leading Epigenetics Product Engine and Advance Pipeline towards the Clinic- CAMBRIDGE, Mass. – June 2, 2010 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round. [...]
Read more »
Posted in Constellation in the News, Newsroom
-Company Leading Emerging Field of Epigenetics- CAMBRIDGE, MA – January 20, 2010 – Constellation Pharmaceuticals, Inc. today announced that it has appointed Garen Bohlin as the company’s Executive Vice President. Mr. Bohlin will be responsible for Constellation’s corporate operations and finance function. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the [...]
Read more »
Posted in Constellation in the News, Newsroom
-Company Leading the Emerging Field of Epigenetics- CAMBRIDGE, MA – January 7, 2010 – Constellation Pharmaceuticals, Inc. today announced that it has appointed Kerry K. Reinertsen, Ph.D. as the company’s Chief Business Officer. Dr. Reinertsen will manage Constellation’s corporate and business development activities, including the formation, implementation and management of research and development alliances to [...]
Read more »
Posted in Constellation in the News, Newsroom
Cambridge, MA – December 23, 2009 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it is selected as one of twenty-eight life sciences companies to participate in $25 million in Tax Incentives awarded by the Massachusetts Life Sciences [...]
Read more »
